Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| TG2-M82H5 | Mouse | Biotinylated Mouse TGF-beta RII / TGFBR2 Protein, His,Avitag™ |  |
|
|
| TG2-H52H5 | Human | Human TGF-beta RII / TGFBR2 Protein, His Tag |  |
|
|
| TG2-H82E4 | Human | Biotinylated Human TGF-beta RII / TGFBR2 Protein, His,Avitag™ |  |
|
|
| TG2-H82F6 | Human | Biotinylated Human TGF-beta RII / TGFBR2 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| TG2-H5252 | Human | Human TGF-beta RII / TGFBR2 Protein, Fc Tag (MALS verified) |  |
|
|
Serial dilutions of Human TGF-beta RII, His Tag (Cat. No. TG2-H52H5) were added into Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) : Biotinylated Human TGF-beta RII, His,Avitag (Cat. No. TG2-H82E4) binding reactions. The half maximal inhibitory concentration (IC50) is 0.39287 μg/mL (QC tested).
The purity of Biotinylated Human TGFBR2, Fc,Avitag (Cat. No. TG2-H82F6) was more than 90% and the molecular weight of this protein is around 110-125 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Netarsudil Dimesylate | AR-13224; AR-13324 | Approved | Aerie Pharmaceuticals | Rhopressa | EU | Ocular Hypertension; Glaucoma, Open-Angle | Aerie Pharmaceuticals Ireland Ltd | 2017-12-18 | Glaucoma, Open-Angle; Ocular Hypertension; Glaucoma; Corneal Edema; Fuchs' Endothelial Dystrophy | Details |
| Netarsudil mesylate/Latanoprost | PG-324 | Approved | Aerie Pharmaceuticals Inc | Rocklatan, Roclanda | EU | Glaucoma, Open-Angle; Ocular Hypertension | Aerie Pharmaceuticals Ireland Ltd | 2019-03-12 | Glaucoma, Open-Angle; Ocular Hypertension | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Adoptive Cell Therapy (Oslo University Hospital) | Phase 2 Clinical | Oslo University Hospital | Colorectal Neoplasms | Details | |
| Trabedersen | OT-101; OT-201; AP-2/09; AP-12009; AP-2/09-DS | Phase 3 Clinical | Isarna Therapeutics | Coronavirus Disease 2019 (COVID-19); Glioblastoma; Pancreatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Melanoma | Details |
| TASO-001 | TASO-001; ATB-301 | Phase 1 Clinical | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z